|
1
|
Hirata H, Hinoda Y, Ueno K, Majid S, Saini
S and Dahiya R: Role of secreted frizzled-related protein 3 in
human renal cell carcinoma. Cancer Res. 70:1896–1905. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan X, Liu Y, Hou J and Cao G: Targeted
therapies for renal cell carcinoma in Chinese patients: Focus on
everolimus. Onco Targets Ther. 8:313–321. 2015.PubMed/NCBI
|
|
3
|
Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L,
Aydin H, Elson P, Zhou M, He H and Zhang H: Enhanced IMP3
Expression Activates NF-кB pathway and promotes renal cell
carcinoma progression. PLoS One. 10:e01243382015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanchez-Gastaldo A, Kempf E, Del Alba
Gonzalez A and Duran I: Systemic treatment of renal cell cancer: A
comprehensive review. Cancer Treat Rev. 60:77–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chandrasekar T, Klaassen Z, Goldberg H,
Kulkarni GS, Hamilton RJ and Fleshner NE: Metastatic renal cell
carcinoma: Patterns and predictors of metastases-A contemporary
population-based series. Urol Oncol. 35:661.e7–661.e14. 2017.
View Article : Google Scholar
|
|
6
|
Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y,
Tong J, Li JM, Wu YL and Yan H: MK2206 enhances the cytocidal
effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR
pathway. Cell Death Dis. 8:e27762017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: an
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alessi DR, Andjelkovic M, Caudwell B, Cron
P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of
protein kinase B by insulin and IGF-1. EMBO J. 15:6541–6551.
1996.PubMed/NCBI
|
|
9
|
Wang C, Wang Q, Li X, Jin Z, Xu P, Xu N,
Xu A, Xu Y, Zheng S, Zheng J, et al: Lycorine induces apoptosis of
bladder cancer T24 cells by inhibiting phospho-Akt and activating
the intrinsic apoptotic cascade. Biochem Biophys Res Commun.
483:197–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Melnik BC: p53: Key conductor of all
anti-acne therapies. J Transl Med. 15:1952017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitajima Y and Miyazaki K: The critical
impact of HIF-1a on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zong S, Li W, Li H, Han S, Liu S, Shi Q
and Hou F: Identification of hypoxia-regulated angiogenic genes in
colorectal cancer. Biochem Biophys Res Commun. 493:461–467. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thomas JD, Zhang YJ, Wei YH, Cho JH,
Morris LE, Wang HY and Zheng XF: Rab1A is an mTORC1 activator and a
colorectal oncogene. Cancer Cell. 26:754–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carew JS, Kelly KR and Nawrocki ST:
Mechanisms of mTOR inhibitor resistance in cancer therapy. Target
Oncol. 6:17–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morishita S, Saito T, Mishima Y, Mizutani
A, Hirai Y and Kawakami M: Pharmacological studies of Senso (Ch'an
Su) containing drugs. Nihon Yakurigaku Zasshi. 87:361–378. 1986.(In
Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu Y, Chen M, Jin XF, Qian C, Xu XM and
Zhang X: Research progress of in vitro and in vivo anti-tumor
effects and formulation of bufalin. Zhongguo Zhong Yao Za Zhi.
39:2829–2833. 2014.(In Chinese). PubMed/NCBI
|
|
17
|
Tian X, Yin H, Zhang S, Luo Y, Xu K, Ma P,
Sui C, Meng F, Liu Y, Jiang Y and Fang J: Bufalin loaded
biotinylated chitosan nanoparticles: An efficient drug delivery
system for targeted chemotherapy against breast carcinoma. Eur J
Pharm Biopharm. 87:445–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, Liu S, Che X, Hou K, Ma Y, Li C,
Wen T, Fan Y, Hu X, Liu Y and Qu X: Bufalin inhibits TGF-β-induced
epithelial-to-mesenchymal transition and migration in human lung
cancer A549 cells by downregulating TGF-β receptors. Int J Mol Med.
36:645–652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang H, Zhang C, Xu L, Zang K, Ning Z,
Jiang F, Chi H, Zhu X and Meng Z: Bufalin suppresses hepatocellular
carcinoma invasion and metastasis by targeting HIF-1α via the
PI3K/AKT/mTOR pathway. Oncotarget. 7:20193–20208. 2016.PubMed/NCBI
|
|
20
|
Yuan XF, Tian HY, Li J, Jin L, Jiang ST,
Liu KW, Luo C, Middleton DA, Esmann M, Ye WC and Jiang RW:
Synthesis of bufalin derivatives with inhibitory activity against
prostate cancer cells. Nat Prod Res. 28:843–847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu F, Tong D, Li H, Liu M, Li J, Wang Z
and Cheng X: Bufalin enhances antitumor effect of paclitaxel on
cervical tumorigenesis via inhibiting the integrin α2/β5/FAK
signaling pathway. Oncotarget. 7:8896–8907. 2016.PubMed/NCBI
|
|
22
|
Li X, Xu P, Wang C, Xu N, Xu A, Xu Y,
Sadahira T, Araki M, Wada K, Matsuura E, et al: Synergistic effects
of the immune checkpoint inhibitor CTLA-4 combined with the growth
inhibitor lycorine in a mouse model of renal cell carcinoma.
Oncotarget. 8:21177–21186. 2017.PubMed/NCBI
|
|
23
|
Rodriguez-Vida A, Hutson TE, Bellmunt J
and Strijbos MH: New treatment options for metastatic renal cell
carcinoma. ESMO Open. 2:e0001852017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu CH, Kan SF, Pu HF, Chien Jea E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu M, Peng S, He Y, Qin M, Cong X, Xing Y,
Liu M and Yi Z: Lycorine is a novel inhibitor of the growth and
metastasis of hormone-refractory prostate cancer. Oncotarget.
6:15348–15361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thaiwong T, Sirivisoot S, Takada M,
Yuzbasiyan-Gurkan V and Kiupel M: Gain-of-function mutation in
PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs. Vet Comp
Oncol. 16:220–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
